AC
NKTR icon

Almitas Capital’s Nektar Therapeutics NKTR Stock Holding History

Almitas Capital’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-307,391
Closed -$3.14M – 96
2025
Q1 		$3.14M Buy
307,391
+246,043
+401% +$3.21M 1.04% 16
2024
Q4 		$856K Hold
61,348
– – 0.19% 57
2024
Q3 		$1.2M Hold
61,348
– – 0.42% 38
2024
Q2 		$1.14M Hold
61,348
– – 0.47% 47
2024
Q1 		$860K Buy
+61,348
New +$642K 0.36% 52

Other funds holding NKTR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Almitas Capital's NKTR Position: Q2 2025 in Review

Almitas Capital sold out of Nektar Therapeutics (NKTR) in Q2 2025, closing a stake of 307,391 shares — an estimated $3.14M sold.

Almitas Capital first reported a position in NKTR in Q1 2024 and held it in 5 quarters. The position peaked at $3.14M in Q1 2025. 109 funds tracked by Wall St. Rank hold NKTR as of Q2 2025.

  • Almitas Capital reported no remaining Nektar Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Almitas Capital sold 307,391 Nektar Therapeutics shares in Q2 2025, an estimated $3.14M.
  • Almitas Capital first reported a position in Nektar Therapeutics in Q1 2024 and held it in 5 quarters.
  • Almitas Capital's Nektar Therapeutics position peaked at $3.14M in Q1 2025.
  • 109 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2025.

Based on Almitas Capital's 13F filing for Q2 2025, filed 14 Aug 2025.